Hedge Fund's AIA Attack Should Have Biotech Cos. Wary
A hedge fund's attempt to invalidate Acorda Therapeutics Inc. drug patents under the America Invents Act as an investment strategy to lower the company's stock price should have biotechnology companies on...To view the full article, register now.
Already a subscriber? Click here to view full article